Human MET/c-Met/HGFR Recombinant Protein (C-His)
- Catalog number: PH14886
- Availability: In Stock
$298.00
- Ex Tax: $298.00
- Description: Recombinant Human MET/c-Met/HGFR Protein, C-His (PH14886) expressed in Mammalian Cells, spanning Met1-Thr932.
Highlights:
• His-Tagged — N-terminal 6×His tag for IMAC purification.
• Mammalian Expression — Proper folding and native glycosylation.
• High Purity — >90% purity verified by SDS-PAGE. - Form: Lyophilized
- Storage buffer: Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
- Purity: >90% as determined by SDS-PAGE.
- Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
- Endotoxin level: Please contact with the lab for this information.
- Expression system: Mammalian Cells
- Protein length: Met1-Thr932
- Predicted molecular weight: 105.10 kDa
- Stability and Storage: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
- Reconstitution: Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
- Alternative Names: Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET
- Species: Homo sapiens (Human)
- Shipping: In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
- Background: Hepatocyte growth factor receptor (MET/HGFR) is a ~155 kDa protein. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. MET is the therapeutic target of amivantamab (Rybrevant).
- Note: For research use only.
Images
-
SDS-PAGESDS-PAGE for Recombinant Human MET/c-Met/HGFR Protein, C-His.
